



The project is supported by



Funded by the Horizon 2020 Framework Programme  
of the European Union

# Introduction to EVBRES

Name of presenter

Date of presentation

# What is EVBRES?

A research and development network promoting collaboration and capacity building for **E**Vidence-**B**ased **RE**Search.

- 4-year EU-funded COST Action (CA17117) running from October 17th 2018 to October 16th 2022.
- A [COST Action](#) is a network dedicated to scientific collaboration, promoting knowledge sharing and pooling of resources. It complements national research funds, optimising investment through research cooperation.



# Our aim

“To encourage researchers and other stakeholders to use an Evidence-Based Research (EBR) approach while carrying out and supporting clinical research – thus avoiding redundant research”.



# The problem


Meta-research (i.e. research on research) indicates that clinical researchers do **NOT**:

- Use a systematic and transparent approach to justify new studies
- Use a systematic and transparent approach to design new studies
- Use a systematic and transparent approach when placing new results in the context of existing results from earlier similar trials

# Why is this important? (1)

When earlier studies are not considered in a systematic and transparent way when justifying and designing new clinical studies:

- Too many redundant studies are performed and published – leading to the waste of time, resources and money
- Too many patients receive unnecessary placebo, or treatment which is incorrect or suboptimal – leading to the waste of health and life



# Why is this important? (2)

When new results are not placed in the context of earlier similar trials in a systematic and transparent way:

- New results of a single study will bias the real results based upon all similar trials including the new study
- Medical reversal will happen as new interventions may be introduced in the clinic without real effect
- The recommendation that further studies are needed may be wrong and lead to new redundant studies.

# Our solution

- To implement «systematicity» and «transparency» in all phases of research.
- To make sure that research is valuable, i.e. “relevant” and “necessary”.



# Stakeholders and Activities

**Aimed at Everyone**  
who Contributes to  
**Clinical Research, including:**


- *Researchers*
- *Clinicians*
- *Patients*
- *Ethics Committees*
- *Research Funders*
- *Publishers*

## **EVBRES** Activities:

- *Collaboration Meetings*
- *Engaging key stakeholders*
- *Publications*
- *Training Schools*
- *Conferences*
- *Online Handbook*
- *Research on research*



# Structure of EVBRES



# Working Groups

To achieve our goal four working groups have been set up each with specific objectives:

WG1: Identifying the implications of an evidence-based approach for key stakeholders: ethics committees, funding agencies, medical journals and patient groups

WG2: Developing a course and handbook for health researchers on how to be evidence-based and why it is important

WG3: Supporting international efforts towards more efficient production and updating of systematic reviews without compromising quality

WG4: Meta-Research on EBR Implementation

# Action Management Committee

- At the present time the EVBRES Action Management Committee consists of over 160 participants representing 37 European countries (including 21 COST Inclusiveness Target Countries).
- Institutions from Australia, Canada, Egypt, Gaza, India, Lebanon, Russia, South Africa, USA are involved as International Partners.

## COST Members


The 38 COST Members are: Albania, Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Moldova, Montenegro, The Netherlands, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, United Kingdom and the former Yugoslav Republic of Macedonia.

These countries govern COST via their representatives in the COST Committee of Senior Officials (CSO) – the General Assembly of the [COST Association](#).

## Cooperating Member

Israel is a Cooperating Member. A Cooperating Member implies non-voting rights in the COST CSO. However, researchers from COST's Cooperating Member enjoy member rights in COST Action participation.

Choose a country in the list above for an overview of the Country National Coordinators (CNC), Action participation and Action Chairs for each Member. A full list of all CSO delegates is available [here](#).





EVBRES participants at the first Workshop meeting in Bergen, Norway. February 2019

Sustainability of  
EVBRES is secured by  
the EBRNetwork



**The Evidence-Based  
Research Network**



# Thank you

ADD PERSONAL EMAIL/TWITTER IF REQUIRED



[www.evbres.eu](http://www.evbres.eu)



@evbres

